Human Antiglobulin Responses

Measuring Immunity: Basic Biology and Clinical Assessment

Volumn , Issue , 2005, Pages 172-186

  Roskos, Lorin K ^a   Kellermann, Sirid Aimée ^a   Foon, Kenneth A ^b  

^a Abgenix Inc   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882837825     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012455900-4/50275-0     Document Type: Chapter

References (110)

1. Abbott Laboratories Adalimumab prescribing information 2002, Abbot Laboratories, North Chicago, IL.
2. Atkinson M.J., Cowan M.J., Feeney A.J. New alleles of IGKV genes A2 and A18 suggest significant human IGKV locus polymorphism. Immunogenetics 1996, 44:115-120.
3. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
4. Baudouin V., Crusiaux A., Haddad E., et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003, 76:459-463.
5. Bhattacharya-Chatterjee M., Chatterjee S.K., Foon K.A. Anti-idiotype antibody vaccine therapy for cancer. Expert Opin Biol Ther 2002, 2:869-881.
6. Buist M.R., Kenemans P., van Kamp G.J., Haisma H.J. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 1995, 40:24-30.
7. Bussiere J.L. Animal models as indicators of immunogenicity of therapeutic proteins in humans. Dev Biol (Basel) 2003, 112:135-139.
8. Chadd H.E., Chamow S.M. Therapeutic antibody expression technology. Curr Opin Biotechnol 2001, 12:188-194.
9. Chatenoud L., Baudrihaye M.F., Chkoff N., Kreis H., Goldstein G., Bach J.F. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986, 137:830-838.
10. Chatenoud L., Jonker M., Villemain F., Goldstein G., Bach J.F. The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science 1986, 232:1406-1408.
11. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001, 61(Suppl 2):58-66.
12. Cosimi A.B., Burton R.C., Colvin R.B., et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981, 32:535-539.
13. Curnow R.T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 1997, 45:210-215.
14. Curtis B.R., Swyers J., Divgi A., McFarland J.G., Aster R.H. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab coated platelets. Blood 2002, 99:2054-2059.
15. Davies J., Jiang L., Pan L.Z., LaBarre M.J., Anderson D., Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 2001, 74:288-294.
16. Denton G.W., Durrant L.G., Hardcastle J.D., Austin E.B., Sewell H.F., Robins R.A. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994, 57:10-14.
17. Dillman R.O. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunocon Radiopharm 1990, 3:1-15.
18. Dillman R.O., Shawler D.L., Dillman J.B., Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984, 2:881-891.
19. Dong X., Storkus W.J., Salter R.D. Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol 1999, 163:5427-5434.
20. Durrant L.G., Doran M., Austin E.B., Robins R.A. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp 72 antigen expressed on colorectal, gastric and ovarian human tumours. Int J Cancer 1995, 61:62-66.
21. Fageberg J., Steinitz M., Wigzell H., Askelof P., Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995, 92:4773-4777.
22. Fearon D.T. Non-structural determinants of immunogenicity and the B cell co-receptors, CD19, CD21, and CD22. Adv Exp Med Biol 1998, 452:181-184.
23. Fearon D.T. The complement system and adaptive immunity. Semin Immunol 1998, 10:355-361.
24. Figlin R.A., Belldegrun A.S., Crawford J., et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002, 21:10a.
25. Foon K.A., Chakraborty M., John W.J., Sherratt A., Kohler H., Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an antidiotype antibody vaccine. J Clin Invest 1995, 96:334-342.
26. Foon K.A., John W.J., Charkraborty M., et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Onco 1999, 17:2889-2895.
27. Foon K.A., John W.J., Chakraborty M., et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997, 3:1267-1276.
28. Gaston R.S., Deierhoi M.H., Patterson T., et al. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991, 39:141-148.
29. Gessner J.E., Heiken H., Tamm A., Schmidt R.E. The IgG Fc receptor family. Ann Hematol 1998, 76:231-248.
30. Gordon R.F., McDade R.L. Multiplexed quantification of human IgG, IgA, and IgM with the FlowMetrix system. Clin Chem 1997, 43:1799-1801.
31. Grimshaw C., Gleason C., Chojnicki E., Young J. Development of an equilibrium immunoassay using electrochemiluminescent detection for a novel recombinant protein product and its application to pre-clinical product development. J Pharm Biomed Anal 1997, 16:605-612.
32. Hanes J., Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997, 94:4937-4942.
33. Herlyn D., Harris D., Zaloudik J., et al. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anticolorectal carcinoma antibody CO17-1A in animals and patients. J Immunother Emphasis Tumor Immunol 1994, 15:303-311.
34. Hooks M.A., Wade C.S., Millikan W.J. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991, 11:26-37.
35. Hougs L., Garred P., Kawasaki T., Kawasaki N., Svejgaard A., Barington T. Three new alleles of IGHG2 and their prevalence in Danish Caucasian, Mozambican Blacks and Japanese. Tissue Antigens 2003, 61:231-239.
36. Huang S.C., Jiang R., Glas A.M., Milner E.C. Non-stochastic utilization of Ig V region genes in unselected human peripheral B cells. Mol Immunol 1996, 33:553-560.
37. Hudson P.J., Souriau C. Engineered antibodies. Nat Med 2003, 9:129-134.
38. Huse W.D., Sastry L., Iverson S.A., et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989, 246:1275-1281.
39. Ignatovich O., Tomlinson I.M., Jones P.T., Winter G. The creation of diversity in the human immunoglobulin V(lambda) repertoire. J Mol Biol 1997, 268:69-77.
40. Isaacs J.D. The antiglobulin response to therapeutic antibodies. Semin Immunol 1990, 2:449-456.
41. Jaffers G.J., Fuller T.C., Cosimi A.B., Russell P.S., Winn H.J., Colvin R.B. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986, 41:572-578.
42. Jefferis R., Lund J. Glycosylation of antibody molecules: structural and functional significance. Chem Immunol 1997, 65:111-128.
43. Jefferis R., Lund J., Pound J.D. IgG-Fc-mediated effector functions: molecular definition of interation sites for effector ligands and the role of glycosylation. Immunol Rev 1998, 163:59-76.
44. Jefferis R., Magged R.A. The specificity and reactivity of rheumatoid factors with human IgG. Monogr Allergy 1989, 26:45-60.
45. Jerne N.K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974, 125C:373-389.
46. Johansson A., Erlandsson A., Eriksson D., et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 2002, 94:1306-1313. 4 Suppl.
47. Juul L., Hougs L., Andersen V., Garred P., et al. Population studies of the human V kappa A18 gene polymorphism in Caucasians, blacks and Eskimos. New functional alleles and evidence for evolutionary selection of a more restricted antibody repertoire. Tissue Antigens 1997, 49:595-604.
48. Kaplan I.V., Levinson S.S. When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. Clin Chem 1999, 45:616-618.
49. Kellermann S.A., Green L.L. Anitbody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 2002, 13:593-597.
50. Khazaeli M.B., Saleh M.N., Wheeler R.H., et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Int 1988, 80:937-942.
51. Klee G.G. Human anti-mouse antibodies. Arch Pathol Lab Med 2000, 124:921-923.
52. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
53. Koren E., Zuckerman L.A., Mire-Sluis A.R. Immune responses to therapeutic proteinsin humans-clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002, 3:349-360.
54. Krapp S., Mimura Y., Jefferis R., Huber R., Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003, 325:979-989.
55. Kress S. Clinical review, Abbott, biologic licensing application, adalimumab-for use in the treatment of rheumatoid arthritis. STN 2002, 125057.
56. Kricka L.J. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999, 45:942-956.
57. Kuroiwa Y., Tomizuka K., Shinohara T., et al. Manipulation of human minichromosomes to carry greater than megabasesized chromosome inserts. Nat Biotechnol 2000, 18:1086-1090.
58. Kuus-Reichel K., Grauer L.S., Karavodin L.M., Knott C., Krusemeier M., Kay N.E. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies". Clin Diagn Lab Immunol 1994, 1:365-372.
59. Li H., Cui X., Pramanik S., Chimge N.O. Genetic diversity of the human immunoglobulin heavy chain VH region. Immunol Rev 2002, 190:53-68.
60. Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol (Paris) 1973, 124:171-184.
61. Lonberg N., Taylor L.D., Harding F.A., et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994, 368:856-859.
62. Mageed R.A., Borretzen M., Moyes S.P., Thompson K.M., Natvig J.B. Rheumatoid factor autoantibodies in health and disease. Ann NY Acad Sci 1997, 815:296-311.
63. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
64. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348:552-554.
65. McCall A.M., Shahied L., Amoroso A.R., et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicyty. J Immunol 2001, 16:6112-6117.
66. Mellstedt H., Frodin J.E., Biberfeld P., et al. Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the "internal image of the antigen' (ab2). Int J Cancer 1991, 48:344-349.
67. Mendez M.J., Green L.L., Corvalan J.R., et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997, 15:146-156.
68. Miller R.A., Oseroff A.R., Stratte P.T., Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983, 62:988-995.
69. Mire-Sluis A.R. Progress in the use of biological assays during the development of biotechnology products. Pharm Res 2001, 18:1239-1246.
70. Mire-Sluis A.R. Challenges with current technology for the detection, measurement and characterization of antibodies against biological therapeutics. Dev Biol (Basel) 2002, 10:59-69.
71. Mittelman A., Chen Z.J., Yang H., Wong G.Y., Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992, 89:466-470.
72. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: mouse antigen binding domains with human constant region domains. Proc Natl Acad Sci USA 1984, 81:6851-6855.
73. Needle M.N. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002, 29(Suppl 14):55-60.
74. Opalka D., Lachman C.E., MacMullen S.A., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115.
75. Ottesen J.L., Nilsson P., Jami J., et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 1994, 37:1178-1185.
76. Palleroni A.V., Aglione A., Labow M., et al. Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997, 17(Suppl 1):S23-S27.
77. Pandey J.P. Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 2000, 19:613-617.
78. Perkins A.C., Pimm M.V., Powell M.C. The implications of patient antibody response for the clinical usefulness of immunoscintigraphy. Nucl Med Commun 1988, 9:273-282.
79. Pimm M.V., Durrant L.G., Baldwin R.W. The influence of syngeneic anti-idiotypic antibody on the biodistribution of an anti-tumour monoclonal antibody in BALB/c mice. Int J Cancer 1989, 43:147-151.
80. Pimm M.V., Perkins A.C., Armitage N.C., Baldwin R.W. The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Me 1985, 26:1011-1023.
81. Pimm M.V., Perkins A.C., Durrant L.G., Baldwin R.W. A rat model for imaging the effect of anti mouse antibody responses on the biodistribution of radiolabelled mouse monoclonal antibodies. Eur J Nucl Med 1988, 14:507-511.
82. Regan J., Campbell K., van Smith L., et al. Characterization of anti-thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA. Transpl Immunol 1997, 5:49-56.
83. Reitan S.K., Hannestad K. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc Natl Acad Sci USA 2002, 99:7588-7593.
84. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
85. Ritter G., Cohen L.S., Williams C., et al. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001, 61:6851-6859.
86. Sasso E.H., Barber C.V., Nardella F.A., Yount W.J., Mannik M. Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The C gamma 2-C gamma 3 interface region contains the major determinants. J Immunol 1988, 140:3098-3107.
87. Schroeder T.J., First M.R., Pouletty C., Hariharan S., Pouletty P. Rapid detection of anti-OKT3 antibodies with the Transtat assay. Transplantation 1993, 55:297-299.
88. Schwartz G., Dutcher J., Vogelzang N., et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol 2002, 21:24a.
89. Scott A.M., Wiseman G., Welt S., et al. A phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin Cancer Res 2003, 9:1639-1647.
90. Sears H.F., Atkinson B., Mattis J., et al. Phase-1 clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982, 1:762-765.
91. Seideman J., Peritt D. A novel monoclonal antibody screening method using the Luminex-100 microsphere system. J Immunol Methods 2002, 267:165-171.
92. Shields R.L., Lai J., Keck R., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277:26733-26740.
93. Stein K.E. Immunogenicity: concepts/issues/concerns. Biologics 2000-comparability of biotechnology products 2002, 15-23. S. Karger, Basel.
94. Stewart T.A., Hollingshead P.G., Pitts S.L., Chang R., Martin L.E., Oakley H. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med 1989, 6:275-281.
95. Stickler M., Mucha J., Estell D., Power S., Harding F. A human dendritic cell-based method to identify CD4+ T-cell epitopes in potential protein allergens. Environ Health Perspect 2003, 111:251-254.
96. Swanson S.J., Mytych D., Ferbas J. Use of biosensors to monitor the immune response. Dev Biol (Basel) 2002, 109:71-78.
97. Tcheng J.E., Kereiakes D.J., Lincoff A.M., et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001, 104:870-875.
98. Tomlinson I.M., Cox J.P., Gherardi E., Lesk A.M., Chotha C. The structural repertoire of the human V kappa domain. EMBO J 1995, 14:4628-4638.
99. Wadhwa M., Bird C., Dilger P., Gaines-Das R., Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 2003, 278:1-17.
100. Wagner C.L., Schantz A., Barnathan E., et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003, 112:37-53.
101. Wang X., Stollar B.D. Immunoglobulin VH gene expression in human aging. Clin Immunol 1999, 93:132-142.
102. Weinblatt M.E., Maddison P.J., Bulpitt K.J., et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 1995, 38:1589-1594.
103. Weiner L.M. An overview of monoclonal antibody therapy of cancer. Semin Oncol 1999, 26(Suppl 12):41-50.
104. Weiner L.M. Monoclonal antibody therapy of cancer. Semin Oncol 1999, 26(Suppl 14):43-51.
105. Weiner L.M., Adams G.P. New approaches to antibody therapy. Oncogene 2000, 19:6144-6151.
106. Welt S., Ritter G., Williams C., et al. Phase I study of anticolon cancer humanized antibody a33. Clin Cancer Res 2003, 9:1338-1346.
107. Welt S., Ritter G., Williams C., et al. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2003, 9:1347-1353.
108. Wierda D., Smith H.W., Zwickl C.M. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 2001, 158:71-74.
109. Winkeler U., Jensen M., Manzke O., Schulz H., Diehl V., Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999, 94:2217-2224.
110. Zwickl C.M., Cocke K.S., Tamura R.N., et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam Appl Toxicol 1991, 16:275-287.